Piribedil and pathological gambling in six parkinsonian patients;Piribedil e Jogo Patológico em seis pacientes parkinsonianos

Arquivos de Neuro-Psiquiatria

Volumn 73, Issue 2, 2015, Pages 115-118

  Micheli, Federico E ^a   Giugni, Juan C ^a   Espinosa, Micke E de Arco ^a   Calvo, Daniela S ^a   Raina, Gabriela B ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Dopamine agonists; Impulse control disorders; Pathological gambling; Piribedil

Indexed keywords

BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA; PAROXETINE; PIRIBEDIL; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPULSION; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EATING DISORDER; FEMALE; HAND TREMOR; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; LOW DRUG DOSE; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PSYCHOTHERAPY; THALAMOTOMY; WALKING DIFFICULTY; CASE REPORT; CHEMICALLY INDUCED; GAMBLING; PSYCHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; FEMALE; GAMBLING; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PIRIBEDIL; RISK FACTORS; TREATMENT OUTCOME;

EID: 84923688068     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/0004-282X20140212     Document Type: Article

References (26)

1. Ávila A, Cardona X, Martín-Baranera M, Bello J, Sastre F. Impulsive and compulsive behaviors in Parkinson’s disease: a one-year followup study. J Neurol Sci. 2011;310(1-2):197-201. http://dx.doi.org/10.1016/j.jns.2011.05.044.
2. Voon V, Hassan K, Zurowski M, Duff-Canning S, Souza M, Fox S et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006;66(11):1750-2. http://dx.doi.org/10.1212/01.wnl.0000218206.20920.4d.
3. Voon V, Hassan K, Zurowski M, Souza M, Thomsen T, Fox S et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006;67(7):1254-7. http://dx.doi.org/10.1212/01.wnl.0000238503.20816.13.
4. Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67(7):1258-61. http://dx.doi.org/10.1212/01.wnl.0000238401.76928.45.
5. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales Kh, Duda JE et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969-73. http://dx.doi.org/10.1001/archneur.63.7.969.
6. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-95. http://dx.doi.org/10.1001/archneurol.2010.65.
7. Molina JA, Sáinz-Artiga MJ, Fraile A, Jiménez-Jiménez FJ, Villanueva C, Ortí-Pareja M et al. Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000;15(5):869-72. http://dx.doi.org/10.1002/1531-8257(200009)15:5,869::AID-MDS1016.3.0.CO;2-I.
8. Gallagher DA, O’Sullivan SS, Evans AH, Lees AJ, Schraq A. Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation: an analysis of published case series. Mov Disord. 2007;22(12):1757-63. http://dx.doi.org/10.1002/mds.21611.
9. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfà F. Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord. 2006;21(12):2068-72. http://dx.doi.org/10.1002/mds.21072.
10. Tschopp L, Salazar Z, Gomez Botello MT, Roca CU,Micheli F et al. Impulse control disorder and piribedil: report of 5 cases. Clin Neuropharmacol. 2010;33(1):11-3. http://dx.doi.org/10.1097/WNF.0b013e3181c4ae2e.
11. Voon V, Thomsen T, Miyasaki JM, Souza M, Shafro A, Fox SH et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64(2):212-6. http://dx.doi.org/10.1001/archneur.64.2.212.
12. Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009;15 4:111-5. http://dx.doi.org/10.1016/S1353-8020(09)70847-8.
13. Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, Antonini A. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23(3):411-5. http://dx.doi.org/10.1002/mds.21872.
14. Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P. Cognitive dysfunctions and pathological gambling in patients with Parkinson’s disease. Mov Disord. 2009;24(6):899-905. http://dx.doi.org/10.1002/mds.22472.
15. Giugni JC, Tschopp L, Escalante V, Micheli F. Dose-dependent impulse control disorders in piribedil overdose. Clin Neuropharmacol. 2012;35 (1):49-50. http://dx.doi.org/10.1097/WNF.0b013e31823d78ab.
16. Kelley BJ, Duker AP, Chiu P. Dopamine agonists and pathologic behaviors. Parkinson’s disease. 2012:ID603631. http://dx.doi.org/10.1155/2012/603631.
17. Weiss HD, Marsh L. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Practice. 2012;2(4):267-74. http://dx.doi.org/10.1212/CPJ.0b013e318278be9b.
18. Ferrara JM, Stacy M. Impulse-control disorders in Parkinson’s disease. CNS Spectr. 2008;13(8):690-8.
19. Raina G, Cersosimo MG, Micheli F. Zoophilia and impulse control disorder in a patient with Parkinson disease. J Neurology. 2012;259 (5):969-70. http://dx.doi.org/10.1007/s00415-011-6270-z.
20. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400-4. http://dx.doi.org/10.1002/ana.22029.
21. Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010;68 (6):963-8. http://dx.doi.org/10.1002/ana.22164.
22. Evidente VG, Esteban RP, Domingo FM, Carbajal LO, Parazo MA. Piribedil as an adjunct to levodopa in advanced Parkinson’s disease: the Asian experience. Parkinsonism Relat Disord. 2003;10(2):117-21. http://dx.doi.org/10.1016/S1353-8020(03)00096-8.
23. Gouraud A, Millaret A, Descotes J, Vial T, French Association of Regional Pharmacovigilance Centres. Piribedil-induced sleep attacks in patients without Parkinson disease: a case series. Clin neuropharmacol. 2011;34(3):104-7. http://dx.doi.org/10.1097/WNF.0b013e31821f0d8b.
24. Tan EK. Piribedil-induced sleep attacks in Parkinson’s disease. Fundam Clin Pharmacol. 2003;17(1):117-9. http://dx.doi.org/10.1046/j.1472-8206.2003.00122.x.
25. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A. Early piribedil monotherapy of Parkinson’s disease: a planned sevenmonth report of the REGAIN study. Mov Disord. 2006;21(12):2110-5. http://dx.doi.org/10.1002/mds.21122.
26. Hastak SM. Treatment of memory impairment, vertigo and tinnitus in the elderly with piribedil in an Indian general practice setting. J Indian Med Assoc. 2003;101(8):500-1.